A comprehensive view of Janssen Global Services LLC.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

J&J’s Janssen unit stops development of HPV, hepatitis B vaccines with Bavarian Nordic but keeps Ebola and HIV vaccine programs; J&J to focus on hepatitis B treatments currently under development, including two combination therapies in Phase 2 studies

Janssen announces new Phase 3 Voyager PAD analyses reinforce benefit of oral Xarelto rivaroxaban and aspirin in patients with peripheral artery disease, various co-morbid conditions; PAD affects 20 million adults in US, with only 8.5 million diagnosed

Janssen gets Health Canada approval of Rybrevant amivantamab bispecific antibody injectable to treat adult patients with advanced or metastatic non-small cell lung cancer pending trial results; lung cancer accounts for 25% of cancer deaths in Canada

ViiV Healthcare, Janssen Pharmaceutical receive FDA approval for label update for Cabenuva cabotegravir, non-nucleoside reverse transcriptase inhibitor rilpivirine injectable to treat HIV-1; approved dose is once-monthly or once every two months

Aspen Pharmacare's South Africa subsidiary announces agreement with Janssen Pharmaceuticals to manufacture and make available an Aspen-branded COVID-19 vaccine, Aspenovax, throughout Africa

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count